Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy

Venetoclax is approved as monotherapy and in combination with rituximab for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Two Phase 1 studies (M12‐175 [NCT01328626]; M13‐365 [NCT01682616]) were conducted in which patients who initially responded and then progressed on venetoclax mono...

Descripción completa

Detalles Bibliográficos
Autores principales: Handunnetti, Sasanka, Anderson, Mary Ann, Roberts, Andrew W., Davids, Matthew S., Ma, Shuo, Boyer, Michelle, Arzt, Jennifer, Masud, Abdullah Al, Popovic, Relja, Jacobson, Amanda, Kim, Su Y., Seymour, John F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175959/
https://www.ncbi.nlm.nih.gov/pubmed/35845292
http://dx.doi.org/10.1002/jha2.177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175959/
https://www.ncbi.nlm.nih.gov/pubmed/35845292
http://dx.doi.org/10.1002/jha2.177

Ejemplares similares